Steven Pearson, ICER president (Jeff Rumans)
ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizumab
Drug pricing watchdog ICER keeps its eye on what price point a drug is best suited for based on clinical benefit — and the group’s newest …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
